tert-Butyl 3-ethynyl-3-hydroxypiperidine-1-carboxylate

Catalog No. :
ACKWGU287
CAS No. :
287192-85-2
Molecular Formula :
C12H19NO3
Molecular Weight :
225.29

IUPAC Name:tert-butyl 3-ethynyl-3-hydroxypiperidine-1-carboxylate

tert-Butyl 3-ethynyl-3-hydroxypiperidine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg97%$120.00Login to see priceIn stockInquiry
250mg97%$180.00Login to see priceIn stockInquiry
1g97%$460.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 3-ethynyl-3-hydroxypiperidine-1-carboxylate
IUPAC Nametert-butyl 3-ethynyl-3-hydroxypiperidine-1-carboxylate
MDL No.MFCD23106003
Molecular FormulaC12H19NO3
Molecular Weight225.29
SMILESOC1(C#C)CN(C(OC(C)(C)C)=O)CCC1
InChI KeyNMCVJBKPWSSTOQ-UHFFFAOYSA-N
Synonym3-Ethynyl-3-hydroxy-piperidine-1-carboxylic acid tert-butyl ester;1-Boc-3-ethynyl-3-hydroxypiperidine;tert-butyl 3-ethynyl-3-hydroxypiperidine-1-carboxylate;1-Piperidinecarboxylic acid, 3-ethynyl-3-hydroxy-, 1,1-dimethylethyl ester;tert-butyl 3-ethynyl-3-hydroxypiperidine-1-carboxylate - [E14932]
CAS No.287192-85-2

Synthetic Route by SureRoute

1. ACKWGU287 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACTFCE561 route compound structure diagram
    ACTFCE56198977-36-7 In Stock
  4. Then
  5. ACKWGU287 route product structure diagram
    ACKWGU287287192-85-2 In Stock
Inquiry

2. ACKWGU287 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Plus
  5. ACTFCE561 route compound structure diagram
    ACTFCE56198977-36-7 In Stock
  6. Then
  7. ACKWGU287 route product structure diagram
    ACKWGU287287192-85-2 In Stock
Inquiry

Comments (0)